CAR models: next generation CAR modifications for enhanced T cell function
T cells genetically targeted with a chimeric antigen receptor (CAR) to B cell malignancies have demonstrated tremendous clinical outcomes. With the proof in principle for CAR T cells as a therapy for B cell malignancies being established, current and future research is being focused on adapting CAR technology to other cancers, as well as enhancing its efficacy and/or safety. The modular nature of the CAR, extracellular antigen binding domain fused to a transmembrane domain and intracellular T cell signaling domains, allows for optimization by replacement of the various components. These modifications are creating a whole new class of therapeutic CARs. In this review, we discuss the recent major advances in CAR design and how these modifications will impact its clinical application.
Molecular therapy oncolytics